Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis
Tarsus Pharmaceuticals has announced that the US Food and Drug Administration (FDA) approved its drug Xdemvy (lotillaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis on 24 July 2023. The company has announced that the drug is now available throughout the US for prescription.
Xdemvy is the only treatment approved by the FDA that directly targets Demodex mites, which are the cause of Demodex blepharitis. Symptoms of the disease include redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base and the presence of collarettes.
Xdemvy is a prescription eyedrop, intended to be administered twice daily, around 12 hours apart, with one drop in each eye, for up to six weeks.
Bobak Azamian, MD PhD, chief executive officer and chairman of Tarsus, commented: “We are delighted that within weeks of FDA approval, Xdemvy is now available to millions of patients with Demodex blepharitis. The efforts of our team have created incredible interest in Xdemvy, the first and only approved solution for this highly prevalent disease. I’m so appreciative of our team and our partners who’ve worked diligently to bring this product to eye care providers and patients quickly and seamlessly following regulatory approval. We are proud to introduce Xdemvy to the eye care community and look forward to its potential to significantly change the way this disease is treated.”
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has …